Literature DB >> 27121570

Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab.

Paul de Boissieu1,2, Thierry Trenque3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27121570     DOI： 10.1007/s00520-016-3238-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  3 in total

1.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

2.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

3.  Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Authors:  Alison T Stopeck; Karim Fizazi; Jean-Jacques Body; Janet E Brown; Michael Carducci; Ingo Diel; Yasuhiro Fujiwara; Miguel Martín; Alexander Paterson; Katia Tonkin; Neal Shore; Paul Sieber; Frank Kueppers; Lawrence Karsh; Denise Yardley; Huei Wang; Tapan Maniar; Jorge Arellano; Ada Braun
Journal:  Support Care Cancer       Date:  2015-09-03       Impact factor: 3.603
  3 in total
  1 in total

1.  Response to letter to the Editors-Safety of long-term denosumab therapy.

Authors:  Alison T Stopeck; Douglas J Warner
Journal:  Support Care Cancer       Date:  2016-11-24       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.